Business Context and Reporting Period
Company: Alight, Inc. (NYSE: ALIT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Alight is a technology-enabled services company providing human capital management solutions, primarily through its "Employer Solutions" segment. The company focuses on employee benefits administration, healthcare navigation, and financial wellbeing via the Alight Worklife platform.
Key Event: On July 12, 2024, the company completed the divestiture of its Payroll and Professional Services businesses (the "Divested Business") for total consideration of up to $1.2 billion. Results of these businesses are reported as discontinued operations.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $2,262 million | $2,332 million | (3.0%) |
| Gross Profit | $765 million | $794 million | (3.7%) |
| Operating Income (Loss) | $(3,090) million | $(90) million | Worsened |
| Net Income (Loss) Attributable to Alight | $(3,097) million | $(157) million | Worsened |
| Adjusted EBITDA | $561 million | $556 million | 0.9% |
| Free Cash Flow | $250 million | $72 million | 247% |
| Total Debt (Principal) | $2,005 million | $2,025 million | (1.0%) |
| Cash and Cash Equivalents | $273 million | $343 million | (20.4%) |
Note: GAAP Net Loss was significantly impacted by a $3,124 million non-cash goodwill impairment charge.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $70 million (3.0%) due to lower Net Commercial Activity and reduced project revenue. Recurring revenue declined 1.3% to $2,108 million.
- Goodwill Impairment: The company recorded a massive $3,124 million non-cash goodwill impairment charge in 2025, driven by a sustained decline in stock price and reduced future financial performance expectations. This charge eliminated goodwill in the Health Solutions reporting unit and reduced Wealth Solutions goodwill to $83 million.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased by $150 million (25.6%) primarily due to lower professional fees related to the divestiture and reduced stock-based compensation.
- Divestiture Impact: The sale of the Payroll and Professional Services businesses resulted in a $1.0 billion cash inflow at closing, plus notes receivable. Discontinued operations reported a net loss of $21 million for 2025.
- Financial Instrument Gains/Losses: The company recorded a $50 million loss on the write-down of the Additional Seller Note from the divestiture, partially offset by a $93 million gain from the change in fair value of the Tax Receivable Agreement (TRA).
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Revenue Growth: Management noted lower than expected bookings and larger than anticipated losses from contract renewals in 2025, which is expected to impact revenue growth in fiscal year 2026.
- Restructuring: The "Post-Separation Plan" (PSP) is underway to optimize operations post-divestiture, with expected pre-tax costs of approximately $65 million and annual savings of over $75 million upon completion.
- Capital Allocation: On February 19, 2026, the company announced it will replace its cash dividend program with deleveraging and share repurchases. As of Dec 31, 2025, $216 million remained authorized for repurchases.
Key Risks & Contingencies:
- Tax Receivable Agreement (TRA) Dispute: The company received an Objection Notice from the TRA Party Representative regarding 2026 payment calculations. A resolution could increase 2026 payments by up to $20 million above the current estimate of $156 million.
- Stock Price Volatility: The stock price ranged from $1.94 to $7.05 in 2025. As of Feb 19, 2026, the price was $0.80, raising concerns about compliance with NYSE minimum share price standards ($1.00 average over 30 days).
- Goodwill Impairment Risk: Continued declines in stock price or financial performance could trigger further impairment charges.
- Divestiture Integration: Risks remain regarding the successful separation of the Divested Business and the realization of contingent consideration.
Investor Verification Checklist
- Goodwill Valuation: Verify the assumptions used in the $3.124 billion impairment calculation, specifically the discount rates (11.25% - 11.75%) and long-term growth rates (3.5%) applied to the Health and Wealth Solutions units.
- TRA Liability: Monitor the resolution of the TRA Objection Notice and its potential impact on 2026 cash outflows (potential $20 million increase).
- NYSE Listing Compliance: Track the 30-day average closing price to ensure compliance with the $1.00 minimum listing standard, given the recent price drop to $0.80.
- Revenue Retention: Analyze the 94% annual revenue retention rate for 2025 and the specific drivers of "larger than anticipated losses from contract renewals."
- Debt Covenants: Review the impact of the goodwill impairment on leverage ratios and compliance with the Credit Agreement covenants.